MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	5/9/2005 7:22:21 AM
	Read Replies (2) of 1826

MGI Pharma upped at Merrill on seen Dacogen approval Monday May 9, 6:56 am ET By Aude Lagorce LONDON (MarketWatch) -- Merrill Lynch upgraded biotech company MGI Pharma, Inc. to buy from neutral, citing increased confidence that cancer drug Dacogen will receive the approval of the U.S. Food and Drug Administration in Sept. and will provide the next leg of earnings-per-share growth. In addition, Merrill said that although Aloxi sales growth have slowed, it expects the drug to continue gaining share, albeit at a lower pace.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next